Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16353
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPerera, Marlon-
dc.contributor.authorKrishnananthan, Nishanth-
dc.contributor.authorLindner, Uri-
dc.contributor.authorLawrentschuk, Nathan-
dc.date2016-09-27-
dc.date.accessioned2016-10-16T22:48:36Z-
dc.date.available2016-10-16T22:48:36Z-
dc.date.issued2016-11-
dc.identifier.citationNature Reviews Urology 2016; 13(11): 641-653en_US
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/16353-
dc.description.abstractGlobally, the increased uptake of serum PSA level screening led to an increase in the number of diagnoses of low-risk and intermediate-risk prostate cancer. Traditionally, these patients have been considered for either active surveillance programmes or radical whole-gland therapies, such as prostatectomy or radiotherapy. Focal therapy is an emerging treatment option that involves the focal ablation of prostate cancer with preservation of surrounding healthy tissue. This approach might result in reduced morbidity when compared with whole-gland therapies. In current practice, much controversy surrounds optimal patient selection and preoperative tumour localization strategies. Focal therapy modalities include cryotherapy, high-intensity focused ultrasound, laser ablation, photodynamic therapy, irreversible electroporation, radiofrequency ablation and focal brachytherapy. However, as long-term oncological data for focal therapies are lacking, formal recommendations for its use cannot be made.en_US
dc.subjectProstate canceren_US
dc.titleAn update on focal therapy for prostate canceren_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleNature Reviews Urologyen_US
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Urology, Kaplan Medical Centre, Pasternak Street, Rehovot, Israelen_US
dc.identifier.affiliationDepartment of Surgical Oncology, Peter MacCallum Cancer Centre, Parkville, Victoria, Australiaen_US
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27670618en_US
dc.identifier.doi10.1038/nrurol.2016.177en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0001-8553-5618en_US
dc.type.austinJournal Articleen_US
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairetypeJournal Article-
crisitem.author.deptSurgery-
crisitem.author.deptUrology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

2
checked on Feb 5, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.